These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 35292919

  • 1. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA, Hebert AA, Zaenglein AL, Silverberg JI, Tan H, Ports WC, Zielinski MA.
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [Abstract] [Full Text] [Related]

  • 2. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J.
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
    Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, Hebert AA.
    Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L, Zhang L, Kobayashi M, Tao X, Qian Q, Cheng H, Liu S, Zhou Y, Chen Y, Zhang J.
    J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
    Silverberg JI, Tallman AM, Ports WC, Gerber RA, Tan H, Zielinski MA.
    Acta Derm Venereol; 2020 Jun 11; 100(13):adv00170. PubMed ID: 32318744
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA.
    Dermatol Ther (Heidelb); 2021 Jun 11; 11(3):845-853. PubMed ID: 33728583
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L, Tao X, Liu S, Cheng H, Fang R, Zhao Y, Cha A, Encinas GA, Zhou Y, Deng Y, Zhang J.
    Dermatol Ther (Heidelb); 2024 May 11; 14(5):1229-1243. PubMed ID: 38748345
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
    Eichenfield LF, Call RS, Forsha DW, Fowler J, Hebert AA, Spellman M, Stein Gold LF, Van Syoc M, Zane LT, Tschen E.
    J Am Acad Dermatol; 2017 Oct 11; 77(4):641-649.e5. PubMed ID: 28823881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.